Current Therapeutic Approaches to Medication-Related Osteonecrosis of the Jaw

Yıl 2018, Cilt: 1 Sayı: 1, 25 - 30, 01.10.2018

Sevinç Kenan Özen Doğan Onur

Öz

Medication-related osteonecrosis of the jaw is a relatively new health problem, which has been affecting an increasing number of cancer and osteoporosis patients each day. Treatment alternatives for this pathology range from conservative therapies to varied surgical interventions. Other treatment alternatives, such as lasers, platelet concentrates, hyperbaric oxygen, ozone therapy, teriparatide, pentoxifylline and alpha-tocopherol, may also be utilized as adjunctive therapies. The generally accepted treatment approach is the palliation of symptoms and controlling associated infection. Because there is a lack of consensus on the ideal treatment approach, many individual factors are considered in the decision-making proccess and the choice of treatment is based on the clinician’s expertise rather than the evidence-based dentistry. In this article, current approaches to the treatment of medication-raleted osteonecrosis of the jaw and their outcomes are discussed in view of available literature

Anahtar Kelimeler

Medication-related osteonecrosis of the jaw, bisphosphonates, conservative treatment, surgical treatment, adjunctive therapies

İlaca Bağlı Çene Kemiği Osteonekrozlarında Güncel Tedavi Yaklaşımları

Öz

İlaca bağlı çene kemiği osteonekrozları nispeten güncel sağlık sorunları olup her geçen gün daha fazla kanser ve osteoporoz hastasını etkilemektedir. Bu alanda mevcut tedavi seçenekleri, konservatif tedavi ve farklı cerrahi uygulamaları kapsamakla birlikte, lazer, trombositten zengin ürünlerin kullanımı, hiperbarik oksijen, ozon tedavisi, parathormon, pentoksifilin ve alfa-tocopherol kullanımı gibi alternatif tedavi yöntemleri destek amaçlı uygulanmaktadır. Tedavide semptomların hafifletilmesi ve enfeksiyon bulgularının giderilmesi yönünde yaklaşım benimsenmektedir. Tedavi yöntemi üzerinde ortak görüş bulunmamakta, karar verme sürecinde hastaya özgü faktörler değerlendirilmekte ve hekimin klinik tecrübesine göre kanıta dayalı olmayan tedavi yaklaşımları tercih edilmektedir. Bu makalede ilaç kullanımlarına bağlı çene osteonekrozlarının tedavilerine yönelik güncel yaklaşımlar ve sonuçları literatür bilgileri eşliğinde tartışılacaktır.

Anahtar Kelimeler

İlaca bağlı çene kemiği osteonekrozu, bifosfonatlar, konservatif tedavi, cerrahi tedavi, destek tedavi

Kaynakça

• Bodem J.P., Kargus S., Engel M., Hoffmann J., Freudls- perger C. (2015): Value of nonsurgical therapeutic ma- nagement of stage I bisphosphonate-related osteonecro- sis of the jaw, J Craniomaxillofac Surg, 43(7): 1139-1143.
• Boff R.C., Salum F.G., Figueiredo M.A., Cherubini K. (2014): Important aspects regarding the role of microor- ganisms in bisphosphonate-related osteonecrosis of the jaws, Arch Oral Biol, 59(8): 790-799.
• Cella L., ve ark. (2011): Autologous bone marrow stem cell intralesional transplantation repairing bisphospho- nate related osteonecrosis of the jaw, Head Face Med, 7: 16.
• Del Fabbro M., Gallesio G., Mozzati M. (2015): Auto- logous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature, Eur J Cancer, 51(1): 62-74.
• Epstein M.S., Wicknick F.W., Epstein J.B., Berenson J.R., Gorsky M. (2010): Management of bisphosphonate-as- sociated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case se- ries, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 110(5): 593–596.
• Fliefel R., Tröltzsch M., Kühnisch J., Ehrenfeld M., Otto S. (2015): Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review, Int J Oral Maxillofac Surg, 44(5): 568–585.
• Freiberger J.J. (2009): Utility of hyperbaric oxygen in tre- atment of bisphosphonate-related osteonecrosis of the jaws, J Oral Maxillofac Surg, 67(5): 96-106.
• Hinchy N.V., ve ark. (2013): Osteonecrosis of the jaw - prevention and treatment strategies for oral health pro- fessionals, Oral Oncol, 49(9): 878-886.
• Ikeda T., ve ark. (2015): Successful treatment of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) patients with sitafloxacin: New strategies for the treatment of BRONJ, Bone, 73: 217–222.
• Karasneh J.A., Al-Eryani K., Clark G.T., Sedghizadeh P.P.(2016): Modified protocol including topical mino- cycline in orabase to manage medication-related os- teonecrosis of the jaw cases, J Oral Pathol Med, 45(9): 718-720
• Khan A.A., ve ark. (2015): Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus, J Bone Miner Res, 30(1): 3–23.
• Kim Y.H., Lee H.K., Song S.I., Lee J.K. (2014): Drug ho- liday as a prognostic factor of medication-related osteo- necrosis of the jaw, J Korean Assoc Oral Maxillofac Surg, 40(5): 206-210.
• Luomanen M., Alaluusua S. (2012): Treatment of bisphosphonate-induced osteonecrosis of the jaws with Nd:YAG laser biostimulation, Lasers Med Sci, 27(1): 251- 255.
• Marx R.E.(2003): Pamidronate (Aredia) and zoledro- nate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, J Oral Maxillofac Surg, 61(9): 1115– 1117.
• Narongroeknawin P., Danila M.I., Humphreys L.G. Jr., Barasch A., Curtis J.R.(2010): Bisphosphonate-associa- ted osteonecrosis of the jaw, with healing after teriparati- de: a review of the literature and a case report, Spec Care Dentist, 30(2): 77-82.
• Otto S., Baumann S., Ehrenfeld M., Pautke C. (2013): Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluo- rescence guided bone resection, J Craniomaxillofac Surg, 41(7): 694-698.
• Ristow O., Otto S., Troeltzsch M., Hohlweg-Majert B., Pautke C. (2015): Treatment perspectives for medicati- on-related osteonecrosis of the jaw (MRONJ), J Cranio- maxillofac Surg, 43(2): 290-293.
• Rugani P., ve ark. (2015): Stage-related treatment con- cept of medication-related osteonecrosis of the jaw-a case series, Clin Oral Investig, 19(6): 1329-1338.
• Ruggiero S.L., ve ark. (2009): American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws -2009 update, J Oral Maxillofac Surg, 67(5): 2–12.
• Ruggiero S.L., ve ark. (2014): American Association of Oral and Maxillofacial Surgeons position paper on me- dication-related osteonecrosis of the jaw-2014 update, J Oral Maxillofac Surg, 72(10): 1938-1956.
• Rupel K., ve ark. (2014): A systematic review of thera- peutical approaches in bisphosphonates-related osteo- necrosis of the jaw (BRONJ), Oral Oncol, 50(11): 1049- 1057.
• Sedghizadeh P.P., ve ark. (2008): Identification of mic- robial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therap, J Oral Maxillofac Surg, 66(4): 767–775.
• Troeltzsch M., ve ark. (2012): Physiology and pharma- cology of nonbisphosphonate drugs implicated in osteo- necrosis of the jaw, J Can Dent Assoc, 78: 85.
• Vercruysse H., Backer T., Mommaerts M.Y. (2014): Out- comes of osseous free flap reconstruction in stage III bisphosphonate-related osteonecrosis of the jaw: Syste- matic review and a new case series, J Craniomaxillofac Surg, 42: 377-386.
• Vescovi P., ve ark. (2010): Surgical approach with Er:- YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT), Lasers Med Sci, 25(1): 101–113.